Home / Business and Economy / Nvidia-Backed Iambic Therapeutics IPO Nets $150M
Nvidia-Backed Iambic Therapeutics IPO Nets $150M
15 Oct
Summary
- Iambic Therapeutics successfully raised $150 million through its initial public offering.
- The clinical-stage cancer drugmaker priced its shares at $16 each.
- Nvidia Corp. is a notable shareholder in Iambic Therapeutics.
Iambic Therapeutics Inc., a company focused on cancer drug development and technology, has secured $150 million through its initial public offering (IPO) in the United States. The IPO's pricing was set at the midpoint of the range initially marketed by the company. This strategic financial move saw Iambic Therapeutics sell approximately 9.38 million shares at a price of $16 per share. Notably, Nvidia Corp. is among the investors backing Iambic Therapeutics. The funds raised are expected to accelerate the company's clinical-stage programs and further its innovative technological pursuits in oncology. The successful IPO underscores investor confidence in Iambic's mission to advance cancer treatments.
